Cite
HARVARD Citation
Bossi, P. et al. (n.d.). Safety and feasibility of every‐other‐week maintenance cetuximab after first‐line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head & neck. 35 (10), pp. 1471-1474. [Online].